Blackstone expands Japan push
Blackstone is increasing exposure to Japanese real estate and reviewing strategic options for its Australian clinical‑trials business, signaling active deal choreography across real assets and healthcare. The moves underline continued cross-border PE activity despite market volatility. (simplywall.st)
Nikkei reported Blackstone will commit $15 billion to Japanese property over three years, with stated targets including data centres, logistics facilities and hotels. (asia.nikkei.com) Blackstone closed on Tokyo Garden Terrace Kioicho for about $2.6 billion earlier this year, marking one of its largest single-asset Japan purchases. (perenews.com) In December Blackstone agreed to acquire Tokyo C‑NX, a five‑storey Grade A logistics complex in Greater Tokyo, for roughly JPY100 billion (about $641 million). (marketscreener.com) Blackstone has engaged advisers as it prepares an auction of Nucleus Network, with recent reports valuing the Australia‑based phase‑1 clinical trials group at A$1 billion-plus (≈US$700m) and naming Goldman Sachs as a sale adviser. (healthcarebusinessinternational.com) A 2025 ACCC report showed Nucleus operated 154 phase‑1 beds in Australia, representing about a 39.4% market share, figures that underpin why regulators and buyers closely scrutinise any CRO transaction. (geopoliticspulse.com) Market sources say potential bidders lining up for Nucleus include Bain Capital, Advent, EQT and Kohlberg—the same global buyout groups that have pursued other APAC CROs such as Novotech. (marketscreener.com) Industry trackers note the Japan purchases and a possible Nucleus sale could alter Blackstone’s revenue mix; Simply Wall St lists Blackstone’s P/E at 28.0 versus a 29.9 industry average as one short‑term valuation metric to monitor. (simplywall.st) Blackstone is also expanding its Japan data‑centre footprint through investments linked to AirTrunk and has publicly described logistics as a “high‑conviction” sector for its real‑estate arm in Japan. (blackstone.com)
